PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.
It’s an cannabinoid class chemical
IUPAC name: N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide
CAS number: 1185887-14-2
Purity: 99,2% min
Appearance: white & yellow powder
The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.